Skip to main content
Explore URMC

Kristen M. O'Dwyer, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-4099

Fax: (585) 273-1051

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Hematology & Oncology



  • Internal Medicine
  • Medical Oncology - American Board of Internal Medicine


MD | University of Wisconsin Medical School

Post-doctoral Training & Residency

07/01/2006 - 06/30/2010
Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center

07/01/2005 - 06/30/2006
Residency in Internal Medicine at New York Presbyterian Hospital

06/14/2004 - 06/30/2005
Internship in Internal Medicine at New York Presbyterian Hospital

07/01/2003 - 06/30/2004
Internship in Pathology at National Cancer Institute

VIEW ALL expand_more


2016 - Present
Young Investigator Award
Sponsor: Southwest Oncology Group (SWOG)

2010 - 2013
Wilmot Cancer Research Fellowship
Sponsor: University of Rochester School of Medicine and Dentistry
Location: Rochester, NY

2009 - 2010
Young Investigator Award
Sponsor: ASCO Cancer Foundation

2007 - 2009
Clinical Scholars Biomedical Research Fellowship
Sponsor: Memorial Sloan-Kettering Cancer Center

2003 - 2004
National Institutes of Health General Research Loan Repayment Program
Sponsor: NIH

2002 - 2003
Howard Hughes Medical Institute Research Training Fellowship for Medical Students
Sponsor: Hughes

2000 - 2002
NIH Research Scholar, Cloister Program
Sponsor: Hughes

Medical Student Teaching Fellowship. Dept. of Physiology
Sponsor: University of Wisconsin School of Medicine
Location: Madison, WI

VIEW ALL expand_more

Clinical Trials

A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Lead Researcher: Kristen M O'Dwyer

This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.

View Study Details

A Phase III Randomized Trial of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Lead Researcher: Kristen M O'Dwyer

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.

View Study Details

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease

Lead Researcher: Kristen M O'Dwyer

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back, or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin and blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

View Study Details

Understanding Causes of Outcome Disparities in Adolescents and Young Adults (AYA) with Acute Lymphoclastic Leukemia (ALL)

Lead Researcher: Kristen M O'Dwyer

We will establish two prospective groups of patients with Acute Lymphoclastic Leukemia (ALL): "Cohort A" will be enrolled on the study at the time of diagnosis while "Cohort B" will be enrolled during maintenance chemotherapy.

View Study Details

PrECOG: Open-Label, Randomized trial of Daunorubicin/Cytarabine and High Dose Cytarabine + Gilteritinib vs Midostaurin for Induction and Consolidation. FLT3 mutated patients will be stratified based on TKD vs ITD. Patients who are FLT3 ITD will be further stratified by Signal Ratio (high vs. low of FLT3 Wild Type) and Nucleophosmin 1-Mutated (NPM1) [positive vs negative].

Lead Researcher: Kristen M O'Dwyer

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during induction and high-dose cytarabine during consolidation. Gilteritinib, is an oral drug that works by stopping the leukemia cells from making the FLT3 protein. This may help stop the leukemia cells from growing faster and thus may help make chemotherapy more effective. Gilteritinib has been approved by the Food and Drug Administration (FDA) for patients who have relapsed or refractory AML with a FLT3 mutation but is not approved by the FDA for newly diagnosed FLT3 AML, and its use in this setting is considered investigational. Midostaurin is an oral drug that works by blocking several proteins on cancer cells, including FLT3 that can help leukemia cells grow. Blocking this pathway can cause death to the leukemic cells. Midostaurin is approved by the FDA for the treatment of FLT3 AML. The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving combination chemotherapy for FLT3 AML.

View Study Details

A Phase Ib Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia

Lead Researcher: Kristen M O'Dwyer

This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being.

View Study Details

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Lead Researcher: Kristen M O'Dwyer

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia.

View Study Details


Journal Articles

Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW. "Evolution of acute myelogenous leukemia stem cell properties after treatment and progression." Blood.. 2016 Sep 29; 128(13):1671-8. Epub 2016 Jul 15.

Tyagi V, Alwaseem H, O'Dwyer KM, Ponder J, Li QY, Jordan CT, Fasan R. "Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs." Bioorganic & medicinal chemistry.. 2016 Sep 1; 24(17):3876-3886. Epub 2016 Jun 16.

O'Dwyer KM, Advani AS. "When to Treat Adults Like Children: Optimizing Therapy for Lymphoblastic Lymphoma in Young Adults." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 Feb 20; 34(6):533-8. Epub 2015 Dec 23.